PCSK9 and diabetes mellitus: The development of monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) has enabled additional potent reductions in LDL-C and, consequently, reduction in cardiovascular risk in patients with and without diabetes [5].